Follow mitoNET 

Copyright © 2018, MitoNET. All Rights Reserved.


Project Leader

Lakshmi N. Yatham, MBBS, FRCPS, MRCPsych, MBA
Professor of Psychiatry, Department of Psychiatry, University of British Columbia
Regional Head of Psychiatry and Regional Program Medical Director for Mental Health and Addictions at Vancouver Coastal Health and Providence Healthcare
Professor, Department of Pharmacology, Therapeutics, University of Manitoba
Principal Investigator and Everett Endowment Fund Chair- Division of Neurodegenerative Disorders, St. Boniface Hospital Research Centre
Research Description
Dr. Yatham's major areas of research interest include neurobiology and treatment of bipolar disorder and major depression. Dr. Yatham's work has been funded by many peer-reviewed funding agencies such as the Canadian Institutes of Health Research (CIHR), Canadian Psychiatric Research Foundation, Stanley Foundation, and National Alliance for Research on Schizophrenia and Depression, USA. He is a member of the College of Reviewers of Canadian Institutes of Health Research (CIHR), was a chair of the Michael Smith Foundation Clinical Scholars Committee and has been a reviewer and a committee member of other peer reviewed funding agencies such as the CIHR. He is a member of the Scientific Advisory Board of the International Bipolar Foundation and Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital in Boston.
Dr. Yatham's major areas of research interest include neurobiology and treatment of bipolar disorder and major depression. Using Positron Emission Tomography brain scanning, his research has provided important insights into the abnormalities in dopaminergic system in mania and the role of brain serotonin 2 receptors in mediating early intervention is effective in halting and reversing the cognitive deficits in bipolar disorder and preventing brain structural changes if mood episodes could be prevented with effective interventions. He has been a lead investigator and a major contributor to many international clinical trials that lead to approval of new treatments for mania and maintenance therapy of bipolar disorder and recently demonstrated in a proof of concept study that cognitive impairment could be treated in bipolar disorder with medications, has published or presented over 200 experimental papers, reviews, book chapters, abstracts, and/or seminars.


Serge Beaulieu, MD, PhD, FRCPC, DFAPA
Associate Professor
Department of Psychiatry
McGill University
Medical Chief, Bipolar Disorders Clinica
Douglas Mental Health University Institute
Research Description
Dr. Beaulieu received peer-reviewed research funding from NARSAD (National Alliance for Research on Schizophrenia and Affective Disorders, USA), The Stanley Foundation (USA), the Canadian Fund for Innovation, FRSQ (Fonds de recherce en sante du Quebec) and CIHR (Canadian Institutes of Health Research). Over the years, his translational research has focused on the regulation of the stress response by the amygdala/limbic system and by antidepressants, using animal models as well as translational approaches in patients suffering from a bipolar disorder. He has also contributed to the testing of new compounds as well as psychotherapeutic and psychoeducative approaches in the treatment of bipolar disorder.
He is also a member of the Board of Governors of CANMAT (Canadian Network on Mood and Anxiety Treatment). Dr. Beaulieu was a member of the Board of Councillors of ISBD (International Society of Bipolar Disorder) for 2006-2008. Dr. Beaulieu was the recipient of the Douglas Utting Prize in 2004, which is awarded to one person in Canada who has contributed significantly to promoting awareness of depression and/or its research and treatment. In addition, he received the prize of the "Medecin-clinicien-enseignant" for 2009. This honour, awarded by The Quebec Medical Association, underlines the exceptional commitment of a doctor having a teaching responsibility in one of the Faculties of Medicine in Quebec. He is a Board member of the community organization Revivre and received two awards in 2017 from AMI-Quebec and the West Island Friends for Mental Health, two well-known community organizations in Montreal.
Glenda MacQueen MD, PhD, FRCPC
Vice Dean, Cumming School of Medicine
University of Calgary
Research Description
Her research interests have focused on mood disorders. She was the 2011 recipient of the Douglas Utting award for studies in depression, the 2014 recipient of the Heinz Lehmann award from the Canadian College of Neuropsychopharmacology and the 2017 recipient of the JM Cleghorn Award for excellence and leadership in clinical research from the Canadian Psychiatric Association.
She is currently the Calgary site lead and co-principal investigator for a CIHR SPOR chronic disease network: Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects: the IMAGINE-SPOR (2016-2021). She is a primary member of the Canadian Open Neuroscience Platform funded by the Brain Canada Foundation (2016-22) and she is a Calgary site lead and coinvestigator on a number of other multi-site projects. She has an H-index of 65 and over 18000 citations.  Clarivate Analytics cited her as a 2016 Highly Cited Researcher (top 1% in field of psychiatry/psychology).
Benjamin Goldstein, MD, PhD, FRCPC
Psychiatris and Professor of Psychiatry, Pharmacology, and Psychological Clinical Science
University of Toronto
Adjunct Professor of Psychiatry, University of Pittsburgh
Director of the Centre for Youth Bipolar Disorder and Director of Research, Department of Psychiatry,
Sunnybrook Health Sciences Centre
Senior Scientist, Sunnybrook Research Institute
Research Description
Dr. Goldstein's efforts focus on teenagers with, or at familial risk for, bipolar disorder. his team seeks to identify clinically relevant biomarkers, and innovative prevention and treatment strategies that focus simultaneously on physical and mental health. Dr. Goldstein has authored over 140 scientific articles, and has received international awards for his research. His research is currently funded by grants from Brain Canada, CIHR, the Heart and Stroke Foundation, and the Ontario Ministry of Research, Innovation and Science. An active educator, Dr. Goldstein serves as Director of the Clinician Scientist Program in the University of Toronto's Department of Psychiatry. With regard to mitochondrial function, Dr. Goldstein has been working for the past 5 years with his collaborator, Dr. Ana Andreazza, on examining measures of mitochondrial function and oxidative stress in relation to mood, neurocognition, vascular structure and function, and multimodal neuroimaging phenotypes. He is interested also in how oxidative stress converges with inflammatory and neurotrophic factors in relation to these phenotypes.
Romina  Mizrahi, PhD, MD
Associate Professor, Psychiatry, University of Toronto
Clinician-Scientist, full member, Institute of Medical Science (IMS), University of Toronto
Full Graduate Faculty Member, Department of Pharmacology & Toxicology, University of Toronto
Director, Focus on Youth Psychosis Prevention (FYPP) clinic and research program at CAMH
Head of Neuroimaging, Early Psychosis Research lab, Research Imaging Centre, CAMH's Campbell Family Mental Health Research Institute
Research Description
Dr. Mizrahii is an Associate Professor in Psychiatry at U of T, Clinical Scientist in the Research Imaging Centre at CAMG, a Full Member of the Institute of Medical Science (IMS) at U of T and  Full Graduate Faculty Member at the Pharmacology & Toxicology Department at U of T. She received funding from the Canadian Institutes of Health Research (CIHR) and the Ontario Mental Health Foundation (OMHF) to study dopamine using positron emission tomography (PET) in early psychosis and in those at risk for the disease. She also leads a new line of research to use a new F-18 radioligand to image neuroinflammation in-vivo and was in charge of translating this radioligand from the bench to the bedside at CAMG. This novel line of research received support of the Scottish Rite Charitable Foundation, the Alzheimer Society of Canada and the Brain & Behaviour Research Foundation to carry out the first human experiments. Using this new radioligand, her lab is currently investigating neuroinflammation in schizophrenia, clinical high risk for psychosis, Alzheimer's disease and mild cognitive impairment. Dr. Mizrahi has recently been awarded a $1.3 million grant from the National Institutes of Mental Health (NIMh) to follow-up on her neuroinflammation work. Dr. Mizrahi has also just started the first human imaging studies of endocannabinoid metabolism in schizophrenia and clinical high risk for psychosis. This work has received initial pilot funding from the Brain & Behavior Research Foundation.